Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07596849RecruitingPhase 3
Testing a New Injection for Graves' Disease
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
Aalst, Oost-VlassAges 18 years+ - NCT07194850RecruitingPhase 2/Phase 3
Study of Efgartigimod for teens with chronic ITP
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
BordeauxAges 12–17 - NCT07525206RecruitingPhase 3
Combination treatment for advanced colorectal cancer
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
Goodyear, ArizonaAges 18 years+ - NCT07216534Recruiting
Virtual reality streetscape study for psychosocial response
This study uses virtual reality to show different versions of your neighborhood to see how it affects your feelings and well-being. You will attend a two-hour visit at Ohio State University.
Columbus, OhioAges 18 years+ - NCT07225569RecruitingPhase 2
Study of a new drug for moderate to severe hidradenitis suppurativa
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
Scottsdale, ArizonaAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Birmingham, AlabamaAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT07610395RecruitingPhase 2
Testing an oral drug for cold virus in COPD patients
This trial tests an oral medication (VPV) to see if it can safely treat rhinovirus (a common cold virus) in people with COPD. The goal is to help you recover faster and prevent serious COPD flare-ups.
Mobile, AlabamaAges 40–85 - NCT07862933Recruiting
AI chat support for older adults with heart failure
This study tests an AI-powered chat system that offers social support to older adults with chronic heart failure. It may help you feel more supported and manage your condition better.
New Taipei City, New Taipei CityAges 60 years+ - NCT07546253Recruiting
Tracking outcomes for brain ablation in drug-resistant epilepsy
This trial is a registry that tracks real-world outcomes for people with drug-resistant epilepsy who are treated with the NeuroOne OneRF ablation system. Participants receive a standard procedure (RF ablation) and their health data is collected to help improve future care.
Miami, FloridaAges Any age - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Mobile, AlabamaAges 18 years+ - NCT07294170Recruiting
Testing Multiple Treatments for Myasthenia Gravis
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Carlsbad, CaliforniaAges 18 years+ - NCT07620392RecruitingPhase 2
Long-Term Safety Study of Afimkibart for Rheumatoid Arthritis
This is a follow-up study for people who already completed a previous trial testing afimkibart (an experimental drug) for rheumatoid arthritis. It checks whether the drug continues to work safely and effectively over a longer period.
Tamarac, FloridaAges 18 years+ - NCT06904066RecruitingPhase 1
Personalized T cell therapy for blood cancers
This trial tests a treatment that takes your own immune cells, modifies them to attack cancer cells, and gives them back to you. It is for people with certain blood cancers who have specific gene changes.
Bethesda, MarylandAges 18–120 - NCT07137598RecruitingPhase 2
A study of RO7790121 for moderate to severe rheumatoid arthritis
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Avondale, ArizonaAges 18 years+ - NCT06163430RecruitingPhase 1/Phase 2
Study of MK-4208 for chronic myeloid leukemia
This trial tests a new pill that may help people with chronic myeloid leukemia (CML) when other treatments have stopped working or caused side effects. It might offer another option for controlling the disease.
Birmingham, AlabamaAges 18 years+ - NCT05805007RecruitingEarly Phase 1
Gene editing treatment for retinitis pigmentosa
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07458347RecruitingPhase 1
Study of a new drug for advanced solid tumors with a KRAS mutation
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
Los Angeles, CaliforniaAges 18 years+ - NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 alone or with other drugs for leukemia
This study tests a new medicine called AZD4512, given alone or with other cancer drugs, for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not improved after treatment. The goal is to see if it can help control the disease.
Duarte, CaliforniaAges 12 years+ - NCT00736749Recruiting
Long-term health check for childhood cancer survivors
This trial tracks the long-term health of people who took part in previous Children's Oncology Group studies. It helps doctors understand the lasting effects of cancer treatment and improve care for survivors.
Birmingham, AlabamaAges Any age - NCT06958536RecruitingPhase 2
Study of brivekimig for moderate-to-severe Crohn's disease
This trial tests a new medicine called brivekimig for people with moderate-to-severe Crohn's disease. It aims to see if the drug can reduce symptoms and inflammation better than standard treatments.
Tucson, ArizonaAges 18–75 - NCT07874750Recruiting
Slow breathing for stress relief in healthy young adults
This study tests whether a 6-week slow-breathing exercise program can lower stress, improve heart rate variability (a sign of healthy heart function), and fix shallow or irregular breathing patterns in healthy young adults between ages 18 and 25. It might help you feel calmer and more in control of your stress.
IstanbulAges 18–25 - NCT07594119RecruitingPhase 3
Testing RAP-219 to reduce seizures in focal epilepsy
This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.
Huntsville, AlabamaAges 18–75 - NCT07805369RecruitingPhase 1
Study of DEM301 for advanced colorectal cancer
This trial tests a new drug called DEM301 for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if DEM301 can help shrink or control the cancer.
Nedlands, Western AustraliaAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.